Oxford Asset Management Sold 714 Shares of United Therapeutics Co. (UTHR)

Oxford Asset Management Sold 714 Shares of United Therapeutics Co. (UTHR)

Oxford Asset Management reduced its position in United Therapeutics Co. (NASDAQ:UTHR) by 5.5% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 12,350 shares of the biotechnology company’s stock after selling 714 shares during the period. Oxford Asset Management’s holdings in United Therapeutics were worth $1,672,000 as of its most recent filing with the SEC.

Other institutional investors have also recently modified their holdings of the company. Northwestern Mutual Investment Management Company LLC boosted its position in shares of United Therapeutics by 6.0% in the first quarter. Northwestern Mutual Investment Management Company LLC now owns 7,748 shares of the biotechnology company’s stock worth $1,049,000 after buying an additional 438 shares in the last quarter. Airain ltd purchased a new position in shares of United Therapeutics during the first quarter worth about $1,784,000. Campbell & CO Investment Adviser LLC purchased a new position in shares of United Therapeutics during the first quarter worth about $204,000. Quantitative Investment Management LLC purchased a new position in shares of United Therapeutics during the first quarter worth about $8,880,000. Finally, Twin Capital Management Inc. boosted its position in shares of United Therapeutics by 54.0% in the first quarter. Twin Capital Management Inc. now owns 43,656 shares of the biotechnology company’s stock worth $5,910,000 after buying an additional 15,308 shares in the last quarter.

Shares of United Therapeutics Co. (NASDAQ UTHR) traded up 3.71% during midday trading on Thursday, hitting $125.37. The stock had a trading volume of 207,126 shares. United Therapeutics Co. has a 12 month low of $97.52 and a 12 month high of $169.89. The stock has a market cap of $5.65 billion, a PE ratio of 8.80 and a beta of 1.42. The stock’s 50-day moving average is $121.73 and its 200-day moving average is $138.79.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, April 26th. The biotechnology company reported $3.89 EPS for the quarter, topping the consensus estimate of $3.12 by $0.77. The company had revenue of $370.50 million for the quarter, compared to the consensus estimate of $399.59 million. United Therapeutics had a return on equity of 41.78% and a net margin of 44.40%. United Therapeutics’s quarterly revenue was up .4% on a year-over-year basis. During the same period last year, the business posted $3.02 EPS. Equities analysts anticipate that United Therapeutics Co. will post $14.42 EPS for the current year.

A number of brokerages recently issued reports on UTHR. Jefferies Group LLC reiterated an “underperform” rating and issued a $105.00 target price (down from $116.00) on shares of United Therapeutics in a report on Friday, April 28th. Wedbush reiterated an “outperform” rating and issued a $213.00 target price (down from $229.00) on shares of United Therapeutics in a report on Thursday, April 27th. Cowen and Company reiterated a “hold” rating and issued a $121.00 target price on shares of United Therapeutics in a report on Wednesday, April 26th. HC Wainwright reiterated a “hold” rating and issued a $95.00 target price on shares of United Therapeutics in a report on Monday, April 17th. Finally, JPMorgan Chase & Co. set a $125.00 target price on United Therapeutics and gave the stock a “hold” rating in a report on Tuesday, April 11th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and two have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $137.09.

In other news, Director Tommy G. Thompson sold 2,000 shares of United Therapeutics stock in a transaction on Wednesday, March 22nd. The stock was sold at an average price of $139.37, for a total value of $278,740.00. Following the transaction, the director now directly owns 2,000 shares in the company, valued at approximately $278,740. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 1,265 shares of United Therapeutics stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $119.40, for a total value of $151,041.00. Following the completion of the transaction, the chief executive officer now owns 1,405 shares in the company, valued at $167,757. The disclosure for this sale can be found here. Insiders have sold a total of 16,953 shares of company stock worth $2,184,928 over the last 90 days. 7.50% of the stock is currently owned by company insiders.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:UTHR”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Related posts

Leave a Comment